Erasca reports Phase 1b data for ERAS-601+cetuximab; MTD 40mg BID; tolerable safety

Erasca, Inc.

Promising initial safety from Phase 1b FLAGSHP-1 dose escalation for ERAS-601 + cetuximab in advanced solid tumors.
Only Grade 1-2 TRAEs at or below the combination MTD; ERAS-601 MTD 40 mg BID 3/1 with cetuximab 500 mg/m2 Q2W.
Data presented at AACR 2023; expects initial Phase 1b dose expansion data in HPV-negative HNSCC in H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.